NASDAQ:KALV KalVista Pharmaceuticals - KALV Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $7.45 +0.64 (+9.40%) (As of 03/29/2023 12:00 AM ET) Add Compare Share Share Today's Range$6.83▼$7.4650-Day Range$6.30▼$8.3952-Week Range$4.12▼$17.06Volume408,098 shsAverage Volume345,340 shsMarket Capitalization$254.57 millionP/E RatioN/ADividend YieldN/APrice Target$19.33 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability KalVista Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside159.5% Upside$19.33 Price TargetShort InterestBearish7.20% of Shares Sold ShortDividend StrengthN/ASustainability-0.82Upright™ Environmental ScoreNews Sentiment0.58Based on 2 Articles This WeekInsider TradingSelling Shares$115,406 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.76) to ($3.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.21 out of 5 starsMedical Sector385th out of 999 stocksPharmaceutical Preparations Industry172nd out of 489 stocks 3.5 Analyst's Opinion Consensus RatingKalVista Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.33, KalVista Pharmaceuticals has a forecasted upside of 159.5% from its current price of $7.45.Amount of Analyst CoverageKalVista Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.20% of the outstanding shares of KalVista Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverKalVista Pharmaceuticals has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in KalVista Pharmaceuticals has recently increased by 13.36%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldKalVista Pharmaceuticals does not currently pay a dividend.Dividend GrowthKalVista Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKalVista Pharmaceuticals has received a 74.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for KalVista Pharmaceuticals is -0.82. Previous Next 2.5 News and Social Media Coverage News SentimentKalVista Pharmaceuticals has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for KalVista Pharmaceuticals this week, compared to 1 article on an average week.MarketBeat Follows2 people have added KalVista Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, KalVista Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $115,406.00 in company stock.Percentage Held by InsidersOnly 8.30% of the stock of KalVista Pharmaceuticals is held by insiders. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for KalVista Pharmaceuticals are expected to grow in the coming year, from ($3.76) to ($3.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of KalVista Pharmaceuticals is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of KalVista Pharmaceuticals is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKalVista Pharmaceuticals has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About KalVista Pharmaceuticals (NASDAQ:KALV) StockKalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.Read More Receive KALV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for KalVista Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address KALV Stock News HeadlinesMarch 22, 2023 | finance.yahoo.comKalVista Pharmaceuticals, Inc. (KALV) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?March 10, 2023 | msn.comSuvretta Capital Management Now Owns 5.30% of Kalvista Pharmaceuticals (KALV)March 29, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. March 3, 2023 | finance.yahoo.comWall Street Analysts See a 155.32% Upside in KalVista Pharmaceuticals, Inc. (KALV): Can the Stock Really Move This High?February 27, 2023 | marketwatch.comHereditary Angioedema Treatment Market Size, Share, Outlook and Forecast to 2028 with Top Countries DataFebruary 27, 2023 | finance.yahoo.comKalVista Pharmaceuticals Presents Data at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual MeetingFebruary 16, 2023 | finance.yahoo.comKalVista Pharmaceuticals to Present Data at the 2023 American Academy of Allergy, Asthma & ImmunologyFebruary 16, 2023 | businesswire.comKalVista Pharmaceuticals to Present Data at the 2023 American Academy of Allergy, Asthma & ImmunologyMarch 29, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. February 14, 2023 | msn.comKalVista stock rises on regulatory guidance for hereditary angioedema therapyFebruary 14, 2023 | finance.yahoo.comKalVista Pharmaceuticals Provides Progress Updates on Sebetralstat DevelopmentFebruary 13, 2023 | nasdaq.comSuvretta Capital Management Cuts Stake in Kalvista Pharmaceuticals (KALV)February 10, 2023 | finance.yahoo.comKalVista Pharmaceuticals Announces Publication of Sebetralstat Phase 2 Data in The LancetFebruary 7, 2023 | finance.yahoo.comWhat Makes KalVista Pharmaceuticals, Inc. (KALV) a New Buy StockFebruary 7, 2023 | finance.yahoo.comWall Street Analysts Think KalVista Pharmaceuticals, Inc. (KALV) Could Surge 149.94%: Read This Before Placing a BetFebruary 7, 2023 | finance.yahoo.comKalVista Pharmaceuticals Presents Data at Western Society of Allergy, Asthma & Immunology (WSAAI) 60th Annual Scientific SessionFebruary 3, 2023 | finance.yahoo.comKalVista Pharmaceuticals to Present at SVB Securities Global Biopharma ConferenceJanuary 27, 2023 | seekingalpha.comTERN Terns Pharmaceuticals, Inc.January 25, 2023 | seekingalpha.comKalVista Pharmaceuticals: The Share Price Rally Requires An Adjustment Of My Investment ThesisJanuary 5, 2023 | marketwatch.comKalVista Pharmaceuticals Names Benjamin Palleiko President >KALVJanuary 5, 2023 | finance.yahoo.comKalVista Pharmaceuticals Announces Benjamin L. Palleiko Promoted to PresidentJanuary 4, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Deciphera Pharmaceuticals (DCPH), Aslan Pharmaceuticals (ASLN) and ADC Therapeutics (ADCT)December 30, 2022 | finance.yahoo.comAfter losing 48% in the past year, KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) institutional owners must be relieved by the recent gainDecember 27, 2022 | markets.businessinsider.comKalVista Pharma Rises; Offers To Sell SharesDecember 27, 2022 | marketwatch.comKalVista Pharma Shares Rise 17% After Direct Offering PricesDecember 27, 2022 | finance.yahoo.comKalVista Pharmaceuticals Announces $58 Million Registered Direct OfferingNovember 14, 2022 | finance.yahoo.comKalVista Pharmaceuticals Presents Patient-Focused Data at American College of Allergy, Asthma & Immunology (ACAAI) 2022 MeetingSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive KALV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for KalVista Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address KALV Company Calendar Last Earnings12/09/2021Today3/29/2023Fiscal Year End4/30/2023Next Earnings (Estimated)7/06/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KALV CUSIPN/A CIK1348911 Webwww.kalvista.com Phone857-999-0075Fax866-553-3269Employees70Year FoundedN/APrice Target and Rating Average Stock Price Forecast$19.33 High Stock Price Forecast$22.00 Low Stock Price Forecast$16.00 Forecasted Upside/Downside+159.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($3.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,340,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-53.53% Return on Assets-48.23% Debt Debt-to-Equity RatioN/A Current Ratio16.56 Quick Ratio16.55 Sales & Book Value Annual Sales$12.69 million Price / Sales20.06 Cash FlowN/A Price / Cash FlowN/A Book Value$7.54 per share Price / Book0.99Miscellaneous Outstanding Shares34,170,000Free Float31,333,000Market Cap$254.57 million OptionableNot Optionable Beta1.12 Key ExecutivesMr. Thomas Andrew Crockett M.B.A. (Age 48)CEO & Director Comp: $980.25kMr. Benjamin L. Palleiko (Age 57)Chief Bus. Officer & CFO Comp: $722.83kDr. Christopher M. Yea Ph.D. (Age 59)Chief Devel. Officer Comp: $664.28kDr. Edward P. Feener Ph.D. (Age 63)Chief Scientific Officer Jarrod AldomVP of Corp. CommunicationsMs. Rachel M. MortenSr. VP of Regulatory Affairs & QADr. Michael D. Smith Pharm.D. (Age 44)Sr. VP of Devel. Dr. Paul K. Audhya M.B.A. (Age 51)M.D., Chief Medical Officer Mr. Stephen DonnellyDirector of Fin. and Company Sec.Mr. John B. McKune (Age 47)VP of Fin. More ExecutivesKey CompetitorsSelecta BiosciencesNASDAQ:SELBSavaraNASDAQ:SVRAORIC PharmaceuticalsNASDAQ:ORICXOMANASDAQ:XOMAAltimmuneNASDAQ:ALTView All CompetitorsInsiders & InstitutionsThomas Andrew CrockettSold 6,700 sharesTotal: $51,322.00 ($7.66/share)Benjamin L PalleikoSold 4,954 sharesTotal: $37,947.64 ($7.66/share)Paul K AudhyaSold 3,412 sharesTotal: $26,135.92 ($7.66/share)Alliancebernstein L.P.Bought 8,636 shares on 2/16/2023Ownership: 0.104%Norges BankBought 218,900 shares on 2/15/2023Ownership: 0.889%View All Insider TransactionsView All Institutional Transactions KALV Stock - Frequently Asked Questions Should I buy or sell KalVista Pharmaceuticals stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for KalVista Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KALV shares. View KALV analyst ratings or view top-rated stocks. What is KalVista Pharmaceuticals' stock price forecast for 2023? 3 Wall Street analysts have issued 12 month price targets for KalVista Pharmaceuticals' stock. Their KALV share price forecasts range from $16.00 to $22.00. On average, they anticipate the company's share price to reach $19.33 in the next twelve months. This suggests a possible upside of 159.5% from the stock's current price. View analysts price targets for KALV or view top-rated stocks among Wall Street analysts. How have KALV shares performed in 2023? KalVista Pharmaceuticals' stock was trading at $6.76 at the beginning of 2023. Since then, KALV shares have increased by 10.2% and is now trading at $7.45. View the best growth stocks for 2023 here. Are investors shorting KalVista Pharmaceuticals? KalVista Pharmaceuticals saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 2,460,000 shares, an increase of 13.4% from the February 28th total of 2,170,000 shares. Based on an average daily volume of 351,700 shares, the short-interest ratio is presently 7.0 days. View KalVista Pharmaceuticals' Short Interest. When is KalVista Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 6th 2023. View our KALV earnings forecast. How were KalVista Pharmaceuticals' earnings last quarter? KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) posted its quarterly earnings results on Thursday, December, 9th. The specialty pharmaceutical company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.79) by $0.01. What ETF holds KalVista Pharmaceuticals' stock ? Invesco Nasdaq Future Gen 200 ETF holds 4,669 shares of KALV stock, representing 0.71% of its portfolio. What other stocks do shareholders of KalVista Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other KalVista Pharmaceuticals investors own include Heron Therapeutics (HRTX), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Catalyst Pharmaceuticals (CPRX), Corbus Pharmaceuticals (CRBP) and Pfizer (PFE). What is KalVista Pharmaceuticals' stock symbol? KalVista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV." Who are KalVista Pharmaceuticals' major shareholders? KalVista Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Frazier Life Sciences Management L.P. (13.16%), Tang Capital Management LLC (12.98%), VR Adviser LLC (11.85%), Jefferies Financial Group Inc. (4.87%), Driehaus Capital Management LLC (4.11%) and Opaleye Management Inc. (3.75%). Insiders that own company stock include Albert Cha, Andreas Maetzel, Benjamin L Palleiko, Christopher Yea, Edward P Feener, Miami Jewish Federatio Greater, Michael David Smith, Paul K Audhya and Thomas Andrew Crockett. View institutional ownership trends. How do I buy shares of KalVista Pharmaceuticals? Shares of KALV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is KalVista Pharmaceuticals' stock price today? One share of KALV stock can currently be purchased for approximately $7.45. How much money does KalVista Pharmaceuticals make? KalVista Pharmaceuticals (NASDAQ:KALV) has a market capitalization of $254.57 million and generates $12.69 million in revenue each year. The specialty pharmaceutical company earns $-82,340,000.00 in net income (profit) each year or ($3.57) on an earnings per share basis. How can I contact KalVista Pharmaceuticals? KalVista Pharmaceuticals' mailing address is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. The official website for the company is www.kalvista.com. The specialty pharmaceutical company can be reached via phone at 857-999-0075, via email at ir@kalvista.com, or via fax at 866-553-3269. This page (NASDAQ:KALV) was last updated on 3/29/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.